Curocell aims to become global CAR-T leader with Rimcato
“Unlike conventional chemical or antibody drugs, CAR-T therapies require development, manufacturing, quality control and logistics to operate as a fully connected system. We believe this approval is meaningful because it marks the first time a Korean company has verified such end-to-end capabilities.”A Korean biotech company has succeeded in developing a CAR..